Gentium S.p.A. Announces Extension of License and Supply and Cost Sharing Agreements with Sigma-Tau Group

VILLA GUARDIA (Como), Italy--(BUSINESS WIRE)--Gentium S.p.A. (Nasdaq: GENT) today announced that it has amended its existing License and Supply and Cost Sharing Agreements with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of Defibrotide in North America, Central America and South America. Gentium will retain exclusive rights to Defibrotide in Europe and the rest of the world.